These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 12733428)
1. Transmissible spongiform encephalopathy update and implications for blood safety. Ricketts MN; Brown P Clin Lab Med; 2003 Mar; 23(1):129-37. PubMed ID: 12733428 [TBL] [Abstract][Full Text] [Related]
2. The risk of accidental transmission of transmissible spongiform encephalopathy: identification of emerging issues. Ramasamy I Public Health; 2004 Sep; 118(6):409-20. PubMed ID: 15313594 [TBL] [Abstract][Full Text] [Related]
4. [Human spongiform encephalopathies in the Netherlands]. Schuur M; Jansen C; Rozemuller AJ; van Gool WA; van Duijn CM Ned Tijdschr Geneeskd; 2009; 153():A173. PubMed ID: 19785856 [TBL] [Abstract][Full Text] [Related]
5. The French surveillance network of Creutzfeldt-Jakob disease. Epidemiological data in France and worldwide. Brandel JP; Peckeu L; Haïk S Transfus Clin Biol; 2013 Sep; 20(4):395-7. PubMed ID: 23587616 [TBL] [Abstract][Full Text] [Related]
9. The public health impact of prion diseases. Belay ED; Schonberger LB Annu Rev Public Health; 2005; 26():191-212. PubMed ID: 15760286 [TBL] [Abstract][Full Text] [Related]
10. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Hewitt PE; Llewelyn CA; Mackenzie J; Will RG Vox Sang; 2006 Oct; 91(3):221-30. PubMed ID: 16958834 [TBL] [Abstract][Full Text] [Related]
11. Transmissible spongiform encephalopathies in humans. Belay ED Annu Rev Microbiol; 1999; 53():283-314. PubMed ID: 10547693 [TBL] [Abstract][Full Text] [Related]
12. The risk of transmitting prion disease by blood or plasma products. Knight R Transfus Apher Sci; 2010 Dec; 43(3):387-391. PubMed ID: 21071277 [TBL] [Abstract][Full Text] [Related]
13. Notification and support for people exposed to the risk of Creutzfeldt-Jakob disease (CJD) (or other prion diseases) through medical treatment (iatrogenically). Ryan R; Hill S; Lowe D; Allen K; Taylor M; Mead C Cochrane Database Syst Rev; 2011 Mar; (3):CD007578. PubMed ID: 21412905 [TBL] [Abstract][Full Text] [Related]
14. Transfusion transmission of human prion diseases. Zou S; Fang CT; Schonberger LB Transfus Med Rev; 2008 Jan; 22(1):58-69. PubMed ID: 18063192 [TBL] [Abstract][Full Text] [Related]
16. Human prion diseases: epidemiology and integrated risk assessment. Glatzel M; Ott PM; Linder T; Gebbers JO; Gmür A; Wüst W; Huber G; Moch H; Podvinec M; Stamm B; Aguzzi A Lancet Neurol; 2003 Dec; 2(12):757-63. PubMed ID: 14636781 [TBL] [Abstract][Full Text] [Related]
17. Advances in screening test development for transmissible spongiform encephalopathies. Cervenakova L; Brown P Expert Rev Anti Infect Ther; 2004 Dec; 2(6):873-80. PubMed ID: 15566331 [TBL] [Abstract][Full Text] [Related]
18. Leucodepletion for transmissible spongiform encephalopathies. St Romaine C; Hazlehurst G; Jewell AP Br J Biomed Sci; 2004; 61(1):48-54. PubMed ID: 15058746 [TBL] [Abstract][Full Text] [Related]